Lakeshore Biopharma (LSB) Competitors $1.20 +0.00 (+0.38%) As of 04/30/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. AVTX, ICCC, IMRX, OTLK, FBLG, KPTI, VNRX, MURA, IMMX, and CUEShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Avalo Therapeutics (AVTX), ImmuCell (ICCC), Immuneering (IMRX), Outlook Therapeutics (OTLK), FibroBiologics (FBLG), Karyopharm Therapeutics (KPTI), VolitionRx (VNRX), Mural Oncology (MURA), Immix Biopharma (IMMX), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Avalo Therapeutics ImmuCell Immuneering Outlook Therapeutics FibroBiologics Karyopharm Therapeutics VolitionRx Mural Oncology Immix Biopharma Cue Biopharma Avalo Therapeutics (NASDAQ:AVTX) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking. Do analysts prefer AVTX or LSB? Avalo Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 562.65%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, AVTX or LSB? Avalo Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Which has higher valuation and earnings, AVTX or LSB? Avalo Therapeutics has higher earnings, but lower revenue than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K120.51-$31.54MN/AN/ALakeshore Biopharma$672.27M0.02-$61.09MN/AN/A Does the MarketBeat Community favor AVTX or LSB? Avalo Therapeutics received 12 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes1248.00% Underperform Votes1352.00% Lakeshore BiopharmaN/AN/A Do institutionals & insiders have more ownership in AVTX or LSB? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor AVTX or LSB? In the previous week, Avalo Therapeutics had 1 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 3 mentions for Avalo Therapeutics and 2 mentions for Lakeshore Biopharma. Lakeshore Biopharma's average media sentiment score of 0.96 beat Avalo Therapeutics' score of 0.93 indicating that Lakeshore Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Avalo Therapeutics Positive Lakeshore Biopharma Positive Is AVTX or LSB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Lakeshore Biopharma N/A N/A N/A SummaryAvalo Therapeutics beats Lakeshore Biopharma on 11 of the 14 factors compared between the two stocks. Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.17M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E RatioN/A7.4422.4218.48Price / Sales0.02242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.146.516.774.25Net Income-$61.09M$143.21M$3.22B$248.23M7 Day Performance-9.77%3.95%3.25%3.29%1 Month Performance-52.19%0.34%0.01%2.42%1 Year PerformanceN/A2.58%18.00%5.54% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma1.3144 of 5 stars$1.20+0.4%N/AN/A$11.17M$672.27M0.00773Short Interest ↓AVTXAvalo Therapeutics3.9073 of 5 stars$4.66+5.7%$33.00+608.2%-70.9%$49.73M$441,000.000.0040News CoverageICCCImmuCell0.9561 of 5 stars$5.47+1.6%N/A+10.4%$49.09M$26.49M-10.9370IMRXImmuneering3.7712 of 5 stars$1.36-1.4%$12.50+819.1%-16.2%$48.81M$320,000.00-0.6960Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap DownOTLKOutlook Therapeutics1.8339 of 5 stars$1.52+3.1%$10.20+573.3%-82.4%$48.51MN/A-0.2020Positive NewsFBLGFibroBiologics2.6691 of 5 stars$1.29-6.9%$13.00+911.7%-88.1%$48.49MN/A-3.7810Short Interest ↓Positive NewsKPTIKaryopharm Therapeutics3.6315 of 5 stars$5.62+4.1%$57.50+923.1%-56.3%$48.46M$145.24M-5.54380Upcoming EarningsShort Interest ↑News CoverageVNRXVolitionRx1.808 of 5 stars$0.48-0.6%$3.33+601.8%-46.7%$47.85M$1.23M-1.3280Analyst ForecastGap UpMURAMural Oncology3.1913 of 5 stars$2.73+1.4%$13.00+376.4%-28.9%$47.02MN/A-0.30119IMMXImmix Biopharma3.3034 of 5 stars$1.70+2.1%$7.00+313.0%-2.8%$46.99MN/A-1.999Upcoming EarningsShort Interest ↓News CoverageCUECue Biopharma4.2229 of 5 stars$0.76-2.7%$3.00+294.7%-60.3%$46.98M$9.29M-0.8460Positive News Related Companies and Tools Related Companies Avalo Therapeutics Competitors ImmuCell Competitors Immuneering Competitors Outlook Therapeutics Competitors FibroBiologics Competitors Karyopharm Therapeutics Competitors VolitionRx Competitors Mural Oncology Competitors Immix Biopharma Competitors Cue Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LSB Stock Free LSB Stock Alerts